BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 25588963)

  • 1. Efficacy and safety of late-start Corifollitropin-alfa administration for controlled ovarian hyperstimulation in IVF: a cohort, case-control study.
    Revelli A; Pittatore G; Casano S; Canosa S; Evangelista F; Benedetto C
    J Assist Reprod Genet; 2015 Mar; 32(3):429-34. PubMed ID: 25588963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial.
    Kolibianakis EM; Venetis CA; Bosdou JK; Zepiridis L; Chatzimeletiou K; Makedos A; Masouridou S; Triantafillidis S; Mitsoli A; Tarlatzis BC
    Hum Reprod; 2015 Feb; 30(2):432-40. PubMed ID: 25492411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Administration of corifollitropin alfa on Day 2 versus Day 4 of the cycle in a GnRH antagonist protocol: a randomized controlled pilot study.
    Blockeel C; Polyzos NP; Derksen L; De Brucker M; Vloeberghs V; van de Vijver A; De Vos M; Tournaye H
    Hum Reprod; 2014 Jul; 29(7):1500-7. PubMed ID: 24813196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial.
    Drakopoulos P; Vuong TNL; Ho NAV; Vaiarelli A; Ho MT; Blockeel C; Camus M; Lam AT; van de Vijver A; Humaidan P; Tournaye H; Polyzos NP
    Hum Reprod; 2017 Nov; 32(11):2225-2233. PubMed ID: 29040589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization.
    Boostanfar R; Shapiro B; Levy M; Rosenwaks Z; Witjes H; Stegmann BJ; Elbers J; Gordon K; Mannaerts B;
    Fertil Steril; 2015 Jul; 104(1):94-103.e1. PubMed ID: 26003273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there a place for corifollitropin alfa in IVF/ICSI cycles? A systematic review and meta-analysis.
    Mahmoud Youssef MA; van Wely M; Aboulfoutouh I; El-Khyat W; van der Veen F; Al-Inany H
    Fertil Steril; 2012 Apr; 97(4):876-85. PubMed ID: 22277766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High ovarian response does not jeopardize ongoing pregnancy rates and increases cumulative pregnancy rates in a GnRH-antagonist protocol.
    Fatemi HM; Doody K; Griesinger G; Witjes H; Mannaerts B
    Hum Reprod; 2013 Feb; 28(2):442-52. PubMed ID: 23136144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progestin primed ovarian stimulation using corifollitropin alfa in PCOS women effectively prevents LH surge and reduces injection burden compared to GnRH antagonist protocol.
    Huang TC; Huang MZ; Seow KM; Yang IJ; Pan SP; Chen MJ; Hwang JL; Chen SU
    Sci Rep; 2021 Nov; 11(1):22732. PubMed ID: 34815477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative incidence of ovarian hyperstimulation syndrome following ovarian stimulation with corifollitropin alfa or recombinant FSH.
    Tarlatzis BC; Griesinger G; Leader A; Rombauts L; Ijzerman-Boon PC; Mannaerts BM
    Reprod Biomed Online; 2012 Apr; 24(4):410-9. PubMed ID: 22386594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol.
    Devroey P; Boostanfar R; Koper NP; Mannaerts BM; Ijzerman-Boon PC; Fauser BC;
    Hum Reprod; 2009 Dec; 24(12):3063-72. PubMed ID: 19684043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-Stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization.
    Devroey P; Fauser BC; Platteau P; Beckers NG; Dhont M; Mannaerts BM
    J Clin Endocrinol Metab; 2004 May; 89(5):2062-70. PubMed ID: 15126522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for in vitro fertilization: a meta-analysis.
    Fensore S; Di Marzio M; Tiboni GM
    J Ovarian Res; 2015 Jun; 8():33. PubMed ID: 26036214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corifollitropin alfa followed by rFSH in a GnRH antagonist protocol for poor ovarian responder patients: an observational pilot study.
    Polyzos NP; Devos M; Humaidan P; Stoop D; Ortega-Hrepich C; Devroey P; Tournaye H
    Fertil Steril; 2013 Feb; 99(2):422-6. PubMed ID: 23084565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF.
    Fauser BC; Alper MM; Ledger W; Schoolcraft WB; Zandvliet A; Mannaerts BM;
    Reprod Biomed Online; 2010 Nov; 21(5):593-601. PubMed ID: 20843746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective randomized trial comparing corifollitropin-α late-start (day 4) versus standard administration (day 2) in expected poor, normal, and high responders undergoing controlled ovarian stimulation for IVF.
    Revelli A; Gennarelli G; Sestero M; Canosa S; Carosso A; Salvagno F; Pittatore G; Filippini C; Benedetto C
    J Assist Reprod Genet; 2020 May; 37(5):1163-1170. PubMed ID: 32185595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility of corifollitropin alfa/GnRH antagonist protocol combined with GnRH agonist triggering and freeze-all strategy in polycystic ovary syndrome patients.
    Hwang JL; Chen SU; Chen HJ; Chen HF; Yang YS; Chang CH; Seow KM; Tzeng CR; Lin YH
    J Formos Med Assoc; 2018 Jun; 117(6):535-540. PubMed ID: 28830648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of highly purified HMG after corifollitropin alfa in antagonist-treated poor ovarian responders: a pilot study.
    Polyzos NP; De Vos M; Corona R; Vloeberghs V; Ortega-Hrepich C; Stoop D; Tournaye H
    Hum Reprod; 2013 May; 28(5):1254-60. PubMed ID: 23442756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome.
    Ragni G; Vegetti W; Riccaboni A; Engl B; Brigante C; Crosignani PG
    Hum Reprod; 2005 Sep; 20(9):2421-5. PubMed ID: 15890731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized dose-response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation.
    Corifollitropin Alfa Dose-finding Study Group
    Hum Reprod; 2008 Nov; 23(11):2484-92. PubMed ID: 18684735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.